CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: In vitro drug sensitivity and outcome

Leukemia and Lymphoma

Volumn 47, Issue 10, 2006, Pages 2076-2083

  Savaşan, Süeyya ^a   Buck, Steven ^a   Raimondi, Susana C ^b   Becton, David L ^c   Weinstein, Howard ^d   Chang, Myron ^e   Ravindranath, Yaddanapudi ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c ARKANSAS CHILDREN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

CD36; Cytarabine; Daunorubicin; Down syndrome; Drug sensitivity; Immunophenotype; Megakaryoblastic leukemia

Indexed keywords

CD11B ANTIGEN; CD33 ANTIGEN; CD36 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD61 ANTIGEN; CD7 ANTIGEN; CYTARABINE; DAUNORUBICIN; FIBRINOGEN RECEPTOR; MICROSOMAL AMINOPEPTIDASE;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLAST CELL; CELL MATURATION; CELL POPULATION; CHILD; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOWN SYNDROME; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; INFANT; MAJOR CLINICAL STUDY; MEGAKARYOBLAST; PRIORITY JOURNAL; TREATMENT OUTCOME; TRISOMY 21;

ADOLESCENT; ADULT; ANTIGENS, CD36; CELL MEMBRANE; CHILD; CHILD, PRESCHOOL; CYTARABINE; DAUNORUBICIN; DOWN SYNDROME; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPHENOTYPING; INFANT; INFANT, NEWBORN; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33750473041     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600773180     Document Type: Article

References (34)

1. Athale, U and Razzouk, B and Raimondi, S and Tong, X and Behm, F and Head, D and (2001) Biology and outcome of childhood acute megakaryoblastic leukemia: A single institution's experience Blood, 97, pp. 3727-3732.
2. Pagano, L and Pulsoni, A and Vignetti, M and (2002) Acute megakaryoblastic leukemia: Experience of GIMEMA trials Leukemia, 16, pp. 1622-1626.
3. Ravindranath, Y and Abella, E and Krischer, J and (1992) Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498 Blood, 80, pp. 2210-2214.
4. Gamis, A and Woods, W and Alonzo, T and Buxton, A and Lange, B and Barnard, D and (2003) Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: A report from the Children's Cancer Group Study 2891 J Clin Oncol, 21, pp. 3415-3422.
5. Ravindranath, Y. (2003) Down syndrome and acute myeloid leukemia: The paradox of increased risk for leukemia and heightened sensitivity to chemotherapy J Clin Oncol, 21, pp. 3385-3387.
6. Kojima, S and Sako, M and Kato, K and (2000) An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome Leukemia, 14, pp. 786-791.
7. Taub, J and Matherly, L and Stout, M and Buck, S and Gurney, J and Ravindranath, Y. (1996) Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: A contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia Blood, 87, pp. 3395-3403.
8. Taub, J and Huang, X and Matherly, L and (1999) Expression of chromosome 21-localized genes in acute myeloid leukemia: Differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin Blood, 94, pp. 1393-1400.
9. Taub, J and Stout, M and Buck, S and (1997) Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin Leukemia, 11, pp. 1594-1595.
10. Zwaan, C and Kaspers, G and Pieters, R and Hahlen, K and Janka-Schaub, G and Zantwijk, C and (2002) Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome Blood, 99, pp. 245-251.
11. Savasan, S and Buck, S and Ravindranath, Y. (2003) CD36 expression is associated with superior in vitro Ara-C sensitivity in acute megakaryoblastic leukemia with and without Down syndrome Med Pediatr Oncol, 41, pp. 274-275. (O-070)
12. Willman, C and Stewart, C. (1989) General principles of multiparameter flow cytometric analysis: Applications of flow cytometry in the diagnostic pathology laboratory Semin Diagn Pathol, 6, pp. 3-12.
13. Terstappen, L and Johnson, D and Mickaels, R and Chen, J and Olds, G and Hawkins, J and (1991) Multidimensional flow cytometric blood cell differentiation without erythrocyte lysis Blood Cells, 17, pp. 585-602.
14. Savasan, S and Buck, S and Ozdemir, O and Hamre, M and Asselin, B and Pullen, J and Ravindranath, Y. (2005) Evaluation of cytotoxicity by flow cytometric drug sensitivity assay in childhood T-cell acute lymphoblastic leukemia Leuk Lymphoma, 46, pp. 833-841.
15. Karandikar, N and Aquino, D and McKenna, R and Kroft, S. (2001) Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome. An immunophenotypic analysis Am J Clin Pathol, 116, pp. 204-210.
16. Carroll, A and Civin, C and Schneider, N and Dahl, N and Pappo, A and Bowman, P and (1991) The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: A Pediatric Oncology Group Study Blood, 78, pp. 748-752.
17. Solary, E and Casasnovas, R and Campos, L and Bene, M and Faure, G and Maingon, P and (1992) Surface markers in adult acute myeloblastic leukemia: Correlation of CD19+, CD34+ and CD14+/DR- phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL) Leukemia, 6, pp. 393-399.
18. Mouthon, M and Freund, M and Titeux, M and Katz, A and Guichard, J and Breton-Gorius, J and Vainchenker, W. (1994) Growth and differentiation of the human megakaryoblastic cell line (ELF-153): A model for early stages of megakaryocytopoiesis Blood, 84, pp. 1085-1097.
19. Tomer, A and Harker, L. (1996) Measurements of in vivo megakaryocytopoiesis: Studies in nonhuman primates and patients Stem Cells, 14(Suppl 1), pp. 18-30.
20. Dastugue, N and Lafage-Pochitaloff, M and Pages, M and Radford, I and Bastard, C and Talmant, P and (2002) Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): A study of the Groupe Francais de Cytogenetique Hematologique (GFCH) Blood, 100, pp. 618-626.
21. Minelli, A and Morerio, C and Maserati, E and Olivier, C and Panarello, C and Bonvin, L and (2001) Meiotic origin of trisomy in neoplasms: evidence in a case of erythroleukaemia Leukemia, 15, pp. 971-975.
22. Wechsler, J and Greene, M and McDevitt, M and Anastasi, J and Karp, J and Le Beau, M and Crispino, J. (2002) Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome Nat Genet, 32, pp. 148-152.
23. Gurbuxani, S and Vyas, P and Crispino, J. (2004) Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome Blood, 103, pp. 399-406.
24. Crispino, J. (2005) GATA1 mutations in Down syndrome: Implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia Pediatr Blood Cancer, 44, pp. 40-44.
25. Sandoval, C and Pine, S and Guo, Q and Sastry, S and Stewart, J and Kronn, D and Jayabose, S. (2005) Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: Case report and review of the literature Pediatr Blood Cancer, 44, pp. 85-91.
26. Harigae, H and Xu, G and Sugawara, T and Ishikawa, I and Toki, T and Ito, E. (2004) The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome Blood, 103, pp. 3242-3243.
27. Elagib, K and Racke, F and Mogass, M and Khetawat, R and Delehanty, L and Goldfarb, A. (2003) RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation Blood, 101, pp. 4333-4341.
28. Shimamoto, T and Ohyashiki, K and Ohyashiki, J and Kawakubo, K and Fujimura, T and Iwama, H and (1995) The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia Blood, 86, pp. 3173-3180.
29. Bourquin, J and Subramanian, A and Langebrake, C and Reinhardt, D and Bernard, O and Ballerini, P and (2006) Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling Proc Natl Acad Sci (USA), 103, pp. 3339-3344.
30. Febbraio, M and Hajjar, D and Silverstein, R. (2001) CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism J Clin Invest, 108, pp. 785-791.
31. Hu, Z and Yang, G and Li, M and Miyamoto, N and Minden, M and McCulloch, E. (1995) Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: Involvement of free radicals Leukemia, 9, pp. 789-798.
32. Padma, M and Das, U. (1996) Effect of cis-unsaturated fatty acids on cellular oxidant stress in macrophage tumor (AK-5) cells in vitro Cancer Lett, 109, pp. 63-75.
33. Capizzi, R and White, J and Powell, B and Perrino, F. (1991) Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine Semin Hematol, 28, pp. 54-69.
34. Yang, M and Li, K and Ng, M and Yuen, P and Fok, T and Li, C and (2003) Thrombospondin-1 inhibits in vitro megakaryocytopoiesis via CD36 Thromb Res, 109, pp. 47-54.